Evidence map›Paper›PMID 41762808›Full record

ArticleBreast (Edinburgh, Scotland)2026

Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.

Junji Tsurutani, Kazuki Nozawa, Toru Mukohara, Tetsuhiko Taira, Akiyo Yoshimura, Shigenori E Nagai, Jun Hashimoto, Kazuo Matsuura, Toshiro Mizuno, Yoshiaki Shinden and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Junji TsurutaniAdvanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. Electronic address: tsurutaj@med.showa-u.ac.jp.
Kazuki NozawaDepartment of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Toru MukoharaDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Tetsuhiko TairaDepartment of Oncology, Sagara Hospital, 3-31 Matsubaracho, Kagoshima, Kagoshima, 892-0833, Japan.
Akiyo YoshimuraDepartment of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 454-8681, Japan.
Shigenori E NagaiDivision of Breast Oncology, Saitama Cancer Center, 780 Komuro, Inamachi, Kita-Adachi-gun, Saitama, 362-0806, Japan.
Jun HashimotoDivision of Medical Oncology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Kazuo MatsuuraDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Toshiro MizunoDepartment of Medical Oncology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Yoshiaki ShindenDepartment of Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
Mitsugu YamamotoDepartment of Breast Oncology, Hokkaido Cancer Center, 2-3-54 Kikusui shi-jo, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan.
Toshimi TakanoDepartment of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Makoto WakaharaDepartment of Breast and Endocrine Surgery, Tottori University Hospital, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan.
Hirofumi TerakawaDepartment of Breast Surgery, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Takashi YamanakaDepartment of Breast Surgery and Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Yasuyuki KojimaInstitute for Clinical Genetics and Genomics, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Takahiro NakayamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, Osaka, 541-8567, Japan.
Yuji HirakawaOncology Medical Science Department I, Daiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8426, Japan.
Kazuhito ShiosakaiData Intelligence Department, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.
Hiroji IwataDepartment of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe real-world EN-SEMBLE (jRCT1030220506) study investigated the effectiveness and safety of treatments subsequent to trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). This post hoc analysis provides informative data for subsequent treatment in patients who discontinue T-DXd due to interstitial lung disease (ILD).

methodsPatients in EN-SEMBLE who discontinued T-DXd due to ILD were included in this analysis. Outcomes for first post-T-DXd treatment were real-world progression-free survival (rwPFS), real-world time to treatment failure (rwTTF), real-world time to next treatment (rwTTNT), and overall survival. ILD recurrence/exacerbation after initiating the first and second post-T-DXd treatments was evaluated.

resultsThis analysis included 146 patients. ILD grade during prior T-DXd treatment was 1, 2, 3, and unknown for 78 (53.4%), 46 (31.5%), 18 (12.3%), and 4 patients (2.7%), respectively. Most patients (81.5%) received subsequent anti-HER2 treatment. rwPFS was 7.2 months (95% confidence interval, 5.4, 10.2), rwTTF 6.5 months (5.1, 9.1), rwTTNT 7.8 months (5.9, 10.8), and overall survival 32.4 months (21.3, not estimable). These outcomes were numerically longer in patients with grade 1 versus 3 ILD during prior T-DXd treatment. Five patients (3.4%) had ILD recurrence during the first post-T-DXd treatment. Among the 93 patients who received second post-T-DXd treatment, 2 (2.2%) experienced ILD recurrence.

conclusionThese findings highlight the importance of early ILD detection and management so patients can receive, and potentially benefit from, subsequent anti-HER2 targeted therapies. ILD recurrence/exacerbation during subsequent therapies was low in patients who experienced ILD with T-DXd.

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsImmunoconjugatesLung Diseases, InterstitialTrastuzumabAdultAgedAntineoplastic Agents, ImmunologicalCamptothecinErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecanInterstitial lung diseaseMetastatic breast cancerSubsequent treatmentTrastuzumab deruxtecan

Identifiers

PMID41762808
PMCPMC12966697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.